51
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategies

, , &
Pages 215-226 | Published online: 20 Jul 2017

References

  • JohnsonNPMuellerJUpdating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemicBull Hist Med200276110511511875246
  • WanPALFarndonPPalmerNMaximizing the value of drug stockpiles for pandemic influenzaEmerg Infect Dis2009151686168719861076
  • MosconaAGlobal transmission of oseltamivir-resistant influenzaN Engl J Med20093601095395619258250
  • TonelliMCicheroEFight against H1N1 influenza A virus: recent insights towards the development of druggable compoundsCurr Med Chem201623181802181726861005
  • LiuCEichelbergerMCCompansRWAirGMInfluenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or buddingJ Virol1995692109911067815489
  • SuzukiTTakahashiTGuoCTSialidase activity of influenza A virus in an endocytic pathway enhances viral replicationJ Virol20057918117051171516140748
  • MatrosovichMNMatrosovichTYGrayTRobertsNAKlenkHDNeuraminidase is important for the initiation of influenza virus infection in human airway epitheliumJ Virol20047822126651266715507653
  • GubarevaLVKaiserLMatrosovichMNSoo-HooYHaydenFGSelection of influenza virus mutants in experimentally infected volunteers treated with oseltamivirJ Infect Dis2001183452353111170976
  • RussellRJHaireLFStevensDJThe structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug designNature20064437107454916915235
  • CollinsPJHaireLFLinYPCrystal structures of oseltamivir-resistant influenza virus neuraminidase mutantsNature200845371991258126118480754
  • WuJTLeungGMLipsitchMCooperBSRileySHedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapyPLoS Med200965e100008519440354
  • ChengPKLeungTWHoECOseltamivir- and amantadine-resistant influenza viruses A (H1N1)Emerg Infect Dis200915696696819523305
  • HurtACHolienJKParkerMWBarrIGOseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza virusesDrugs200969182523253119943705
  • MeijerALackenbyAHungnesOOseltamivir-resistant influenza virus A (H1N1), Europe, 2007–08 seasonEmerg Infect Dis200915455256019331731
  • KisoMShinyaKShimojimaMCharacterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A virusesPLoS Pathog201068e100107920865125
  • UjikeMShimabukuroKMochizukiKOseltamivir-resistant influenza viruses A (H1N1) during 2007–2009 influenza seasons, JapanEmerg Infect Dis201016692693520507742
  • ChenHCheungCLTaiHOseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, ChinaEmerg Infect Dis200915121970197219961677
  • RegoesRRBonhoefferSEmergence of drug-resistant influenza virus: population dynamical considerationsScience2006312577238939116627735
  • HandelALonginiIMJrAntiaRNeuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spreadPLoS Comput Biol2007312e24018069885
  • LipsitchMCohenTMurrayMLevinBRAntiviral resistance and the control of pandemic influenzaPLoS Med200741e1517253900
  • MoghadasSMBowmanCSRöstGWuJPopulation-wide emergence of antiviral resistance during pandemic influenzaPLoS One200833e183918350174
  • EichnerMSchwehmMDuerrHPAntiviral prophylaxis during pandemic influenza may increase drug resistanceBMC Infect Dis20099419154598
  • Van Den DoolCHakEBontenMJWallingaJA model-based assessment of oseltamivir prophylaxis strategies to prevent influenza in nursing homesEmerg Infect Dis200915101547155519861044
  • HandelALonginiIMJrAntiaRAntiviral resistance and the control of pandemic influenza: the roles of stochasticity, evolution and model detailsJ Theor Biol2009256111712518952105
  • BaccamPBeaucheminCMackenCAHaydenFGPerelsonASKinetics of influenza A virus infection in humansJ Virol200680157590759916840338
  • KisoMMitamuraKSakai-TagawaYResistant influenza A viruses in children treated with oseltamivir: descriptive studyLancet2004364943675976515337401
  • NowarkMAMayRMVirus Dynamics: Mathematical Principles of Immunology and VirologyOxfordOxford University Press2000
  • FooJMichorFEvolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategiesPLoS Comput Biol2009511e100055719893626
  • TaylorHMKarlinSAn Introduction to Stochastic ModelingWaltham, MAAcademic Press1994
  • AntiaRRegoesRRKoellaJCBergstromCTThe role of evolution in the emergence of infectious diseasesNature2003426696765866114668863
  • LiaoCMYangSCChioCPChenSCUnderstanding influenza virus-specific epidemiological properties by analysis of experimental human infectionsEpidemiol Infect2010138682583519919730
  • LiaoCMHsiehNHChioCPChenSCAssessing the exacerbations risk of influenza-associated chronic occupational asthmaRisk Anal20103071062107520409032
  • CaniniLConwayJMPerelsonASCarratFImpact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling studyPLoS Comput Biol2014104e100356824743564
  • ChenSCHsiehNHYouSHWangCHLiaoCMBehavioural response in educated young adults towards influenza A (H1N1) pdm09Epidemiol Infect201514391846185725359684
  • HaydenFGFritzRLoboMCAlvordWStroberWStrausSELocal and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defenseJ Clin Invest199810136436499449698
  • DobrovolnyHMReddyMBKamalMARaynerCRBeaucheminCAAssessing mathematical models of influenza infections using features of the immune responsePLoS One201382e5708823468916
  • Ben-ShacharRKoelleKMinimal within-host dengue models highlight the specific roles of the immune response in primary and secondary dengue infectionsJ R Soc Interface2015121032014088625519990
  • DasSRHensleySEDavidAFitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategyProc Natl Acad Sci U S A201110851E1417E142222106257
  • LeeNChanPKHuiDSViral loads and duration of viral shedding in adult patients hospitalized with influenzaJ Infect Dis2009200449250019591575
  • De ClercqEAntiviral agents active against influenza A virusesNat Rev Drug Discov20065121015102517139286
  • ParvinJDMosconaAPanWTLeiderJMPalesePMeasurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1J Virol19865923773833016304
  • DrakeJWRates of spontaneous mutation among RNA virusesProc Natl Acad Sci U S A1993909417141758387212
  • NobusawaESatoKComparison of the mutation rates of human influenza A and B virusesJ Virol20068073675367816537638
  • YenHLHerlocherLMHoffmannENeuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibilityAntimicrob Agents Chemother200549104075408416189083
  • DuvalXvan der WerfSBlanchonTEfficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trialPLoS Med2010711e100036221072246